Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

BioScrip Inc (BIOS): GAMCO Investors Still Bullish and Buys More Shares

Page 1 of 2

GAMCO Investors and other funds managed by Mario Gabelli continue to aggressively add to their holdings in BioScrip Inc (NASDAQ:BIOS), having increased their position by another 719,418 shares, according to GAMCO’s latest 13D filing with the SEC. All told, GAMCO and its affiliates have now obtained nearly 7.3 million shares, giving them a 10.62% stake in BioScrip, with Gabelli Funds owning the majority of the aggregate stake, holding 4.89 million shares.

Mario Gabelli

GAMCO Investors, founded in 1986 by incumbent manager Mario Gabelli, has been one of the most successful funds of the past three decades. With an equity portfolio now valued at over $18 billion, and assets under management of over $30 billion, the fund has kept pace with the ever changing financial industry, remaining both relevant and lucrative. In particular, their small cap picks have proven especially successful, beating the S&P 500 by several percentage points annually.

When we last reported on GAMCO’s bullish stance on BioScrip Inc (NASDAQ:BIOS), they had just obtained another 700,000 shares between August 7 and October 24, bringing their total up to 5.86 million shares. In another filing on December 4, they disclosed upping that total by another 700,000 to 6.57 million, leading up to the current disclosure of yet another 700,000 shares. That made them BioScrip’s largest shareholder among institutional investors at the time, a position they still hold to this day.

BioScrip Inc (NASDAQ:BIOS) has had a rocky run over the past 18 months, as its stock has crumbled 65% since a 10-year high on August 2, 2013. That downward momentum has continued right into this year, with the stock down over 16% year-to-date, to just $5.75. The pharmacy and home health care services provider’s most recent quarterly earnings report came in well below analysts expectations, with a reported loss of $0.42 cents per share on a net loss of $28.3 million, against an expected loss of just $0.02 cents per share. That followed a year-ago period in which BioScrip earned $1.6 million and $0.01 cent per share. Despite the losses, revenue did greatly increase from the year-ago period, rising to $244 million from $190.6 million.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!